To include your compound in the COVID-19 Resource Center, submit it here.

Vismodegib: Interim Phase II data

Interim data from 29 evaluable patients who completed an average of 6 months of treatment in an 18-month, double-blind, U.S. Phase II trial showed that once-daily 150 mg oral vismodegib significantly reduced the

Read the full 333 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE